| Autor: |
Alter HJ; Transfusion Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA., Barnes E; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Biondi MJ; School of Nursing, York University, Toronto, ON, Canada., Cox AL; The Johns Hopkins University School of Medicine, Baltimore, MD, USA., Eberts JD; 1Day Sooner, Washington, DC, 20002, USA, University of Toronto, Toronto, ON, Canada. Electronic address: jake.eberts@1daysooner.org., Feld JJ; Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, ON, Canada., Liang TJ; Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA., Morrison J; 1Day Sooner, Claymont, DE, USA., Rice CM; Laboratory of Virology and Infectious Disease, Rockefeller University, New York, NY, USA; Departments of Medicine and of Microbiology and Immunology, Université de Montréal, Montréal, QC, Canada., Shoukry NH; Laboratory of Liver Immunology, University of Montreal Hospital Research Centre (CRCHUM), Montréal, QC, Canada., Thomas DL; The Johns Hopkins University School of Medicine, Baltimore, MD, USA., Van Gennip J; Action Hepatitis Canada, Montréal, QC, Canada., Weijer C; Departments of Philosophy, Medicine, and Epidemiology and Biostatistics, Western University, London, ON, Canada. |
| Abstrakt: |
Competing Interests: The views expressed above are those of the individual signatories, and do not necessarily represent an endorsement by their institutions. JDE and JM are employees of 1Day Sooner, which organised this letter and has received funding from Open Philanthropy in support of its hepatitis C-related work. MJB has received research grants from AbbVie, Gilead, and Cepheid. JJF has received research grants from AbbVie and Gilead, and consulting payments from AbbVie, Gilead, Arbutus, GSK, Roche, Vir, and Janssen. JVG's organisation has received payments from AbbVie, Gilead, and Cepheid, and JVG has participated in data safety monitoring boards or advisory boards for AbbVie and Gilead. ALC and DLT are professors at The Johns Hopkins University, which has received funding from the US National Institutes of Health (NIH; 5U19AI159822-03) for hepatitis C vaccine development; ALC is a principal investigator on several subprojects. EB is a principal investigator on another subproject under the same NIH grant. DLT owns stock in Excision Bio, has received consulting payments from Excision Bio and Everys Bio and payment from Merck for participation on an advisory board. CW has received consulting fees from Eli Lilly & Company, Cardialen, and Research Triangle Institute International. HJA, TJL, and NHS declared no competing interests. |
